These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
407 related articles for article (PubMed ID: 1568213)
1. Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine. Allen TM; Mehra T; Hansen C; Chin YC Cancer Res; 1992 May; 52(9):2431-9. PubMed ID: 1568213 [TBL] [Abstract][Full Text] [Related]
2. Therapy of central nervous system leukemia in mice by liposome-entrapped 1-beta-D-arabinofuranosylcytosine. Hong F; Mayhew E Cancer Res; 1989 Sep; 49(18):5097-102. PubMed ID: 2766280 [TBL] [Abstract][Full Text] [Related]
3. Multivesicular liposomes containing cytarabine for slow-release Sc administration. Kim S; Howell SB Cancer Treat Rep; 1987 May; 71(5):447-50. PubMed ID: 3567968 [TBL] [Abstract][Full Text] [Related]
4. Effect of cholesterol content on antitumor activity and toxicity of liposome-encapsulated 1-beta-D-arabinofuranosylcytosine in vivo. Ganapathi R; Krishan A; Wodinsky I; Zubrod CG; Lesko LJ Cancer Res; 1980 Mar; 40(3):630-3. PubMed ID: 7471083 [TBL] [Abstract][Full Text] [Related]
5. [Influencing factors in the leakage of liposome and arabinoside cytosine (ARA-C) entrapped in liposomes in treatment of L1210 mouse leukemia]. Fu NW Zhonghua Zhong Liu Za Zhi; 1985 Jul; 7(4):250-3. PubMed ID: 4085312 [TBL] [Abstract][Full Text] [Related]
6. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity. Li C; Wang C; Yang H; Zhao X; Wei N; Cui J J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Allen TM; Hansen C Biochim Biophys Acta; 1991 Sep; 1068(2):133-41. PubMed ID: 1911826 [TBL] [Abstract][Full Text] [Related]
8. Role of liposome type and route of administration in the antitumor activity of liposome-entrapped 1-beta-D-arabinofuranosylcytosine against mouse L1210 leukemia. Rustum YM; Dave C; Mayhew E; Papahadjopoulos D Cancer Res; 1979 Apr; 39(4):1390-5. PubMed ID: 421223 [No Abstract] [Full Text] [Related]
9. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Huang SK; Mayhew E; Gilani S; Lasic DD; Martin FJ; Papahadjopoulos D Cancer Res; 1992 Dec; 52(24):6774-81. PubMed ID: 1458465 [TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of a water-insoluble compound entrapped in liposomes on L1210 leukemia in mice. Brassinne C; Atassi G; Frühling J; Penasse W; Coune A; Hildebrand J; Ruysschaert JM; Laduron C J Natl Cancer Inst; 1983 Jun; 70(6):1081-6. PubMed ID: 6574278 [TBL] [Abstract][Full Text] [Related]
11. Distribution and metabolism of lipsome-encapsulated and free 1-beta-D-arabinofuranosylcytosine (Ara-C) in dog and mouse tissues. Ellens H; Rustum Y; Mayhew E; Ledesma E J Pharmacol Exp Ther; 1982 Aug; 222(2):324-30. PubMed ID: 7097552 [TBL] [Abstract][Full Text] [Related]
12. Chemotherapeutic efficacy of Nocodazole encapsulated in liposomes on L1210 murine leukemia. Laduron C; Coune A; Atassi G; Hildebrand J; Ruysschaert JM; Stryckmans P; Brassinne C Res Commun Chem Pathol Pharmacol; 1983 Mar; 39(3):419-36. PubMed ID: 6190203 [TBL] [Abstract][Full Text] [Related]
13. Multivesicular liposomes containing 1-beta-D-arabinofuranosylcytosine for slow-release intrathecal therapy. Kim S; Kim DJ; Geyer MA; Howell SB Cancer Res; 1987 Aug; 47(15):3935-7. PubMed ID: 3607740 [TBL] [Abstract][Full Text] [Related]
14. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice. Chandrasekaran B; Capizzi RL; Kute TE; Morgan T; Dimling J Cancer Res; 1989 Jun; 49(12):3259-66. PubMed ID: 2720678 [TBL] [Abstract][Full Text] [Related]
15. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Gabizon A; Catane R; Uziely B; Kaufman B; Safra T; Cohen R; Martin F; Huang A; Barenholz Y Cancer Res; 1994 Feb; 54(4):987-92. PubMed ID: 8313389 [TBL] [Abstract][Full Text] [Related]
16. The treatment of intravenously implanted Lewis lung carcinoma with two sustained release forms of 1-beta-D-arabinofuranosylcytosine. Rahman YE; Patel KR; Cerny EA; Maccoss M Eur J Cancer Clin Oncol; 1984 Aug; 20(8):1105-12. PubMed ID: 6540691 [TBL] [Abstract][Full Text] [Related]
17. 6-mercaptopurine (6-MP) entrapped stealth liposomes for improvement of leukemic treatment without hepatotoxicity and nephrotoxicity. Umrethia M; Ghosh PK; Majithya R; Murthy RS Cancer Invest; 2007 Mar; 25(2):117-23. PubMed ID: 17453823 [TBL] [Abstract][Full Text] [Related]
18. Production of N4-succinyl-1-beta-D-arabinofuranosylcytosine, a novel metabolite of N4-behenoyl-1-beta-D-arabinofuranosylcytosine, in mice and its biological significance. Oh-ishi J; Kataoka T; Tsukagoshi S; Sakurai Y; Shibukawa M; Kobayashi H Cancer Res; 1981 Jun; 41(6):2501-6. PubMed ID: 7237444 [TBL] [Abstract][Full Text] [Related]
19. Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone. Gokhale PC; Pei J; Zhang C; Ahmad I; Rahman A; Kasid U Anticancer Res; 2001; 21(5):3313-21. PubMed ID: 11848489 [TBL] [Abstract][Full Text] [Related]
20. Comparison of lymphatic uptake, metabolism, excretion, and biodistribution of free and liposome-entrapped [14C]cytosine beta-D-arabinofuranoside following intraperitoneal administration to rats. Parker RJ; Priester ER; Sieber SM Drug Metab Dispos; 1982; 10(1):40-6. PubMed ID: 6124381 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]